Marc A. Brockmann

Dr. Marc A. Brockmann

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2012 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
DBDaniel Buergy
Daniel Buergy
FWFrederik Wenz
Frederik Wenz
CGChristoph Groden
Christoph Groden
MBMarc A. Brockmann
Marc A. Brockmann

30 September 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HBHanne Boll
Hanne Boll
SNStefanie Nittka
Stefanie Nittka
FDFabian Doyon
Fabian Doyon
MNMichael Neumaier
Michael Neumaier
AMAlexander Marx
Alexander Marx
MBMarc A. Brockmann
Marc A. Brockmann
Micro-CT imaging of liver disease in mice relies on high soft tissue contrast to detect small lesions like liver metastases. Purpose of this study was to characterize the localization and time course of contrast enhancement of a nanoparticular alkaline earth metal-based contrast agent (VISCOVER ExiTron nano) developed for small animal liver CT imaging. ExiTron nano 6000 and ExiTron nano 12000, formulated for liver/spleen imaging and angiography, respectively, were intravenously injected in C57BL/6J-mice. The distribution and time course of contrast enhancement were analysed by repeated micro-CT up to 6 months. Finally, mice developing liver metastases after intrasplenic injection of colon carcinoma cells underwent longitudinal micro-CT imaging after a single injection of ExiTron nano. After a single injection of ExiTron nano the contrast of liver and spleen peaked after 4–8 hours, lasted up to several months and was tolerated well by all mice. In addition, strong contrast enhancement of abdominal and mediastinal lymph nodes and the adrenal glands was observed. Within the first two hours after injection, particularly ExiTron nano 12000 provided pronounced contrast for imaging of vascular structures. ExiTron nano facilitated detection of liver metastases and provided sufficient contrast for longitudinal observation of tumor development over weeks. The nanoparticulate contrast agents ExiTron nano 6000 and 12000 provide strong contrast of the liver, spleen, lymph nodes and adrenal glands up to weeks, hereby allowing longitudinal monitoring of pathological processes of these organs in small animals, with ExiTron nano 12000 being particularly optimized for angiography due to its very high initial vessel contrast.

1 June 2005 in Journal of Neurosurgery
Verified
Journal Article
Closed access
MBMarc A. Brockmann
Marc A. Brockmann
GNGeorg Nowak
Georg Nowak
ERErich Reusche
Erich Reusche
MRMartin Russlies
Martin Russlies
DPDirk Petersen
Dirk Petersen
✓ Supratentorial subdural hematoma is a well-known complication following spinal interventions. Less often, spinal or supratentorial interventions cause remote cerebellar hemorrhage (RCH). The exact pathomechanism accounting for RCH remains unclear, but an interventional or postinterventional loss of cerebrospinal fluid (CSF) seems to be involved in almost all cases. Hemorrhage is often characterized by a typical, streaky bleeding pattern due to blood spreading in the cerebellar sulci. Three different cases featuring this bleeding pattern following spinal, supratentorial, and thoracic surgery are presented. Possible pathomechanisms leading to RCH are discussed. Based on data from the underlying cases and the reviewed literature, the authors concluded that this zebra-pattern hemorrhage seems to be typical in a postoperative loss of CSF, which should always be considered on presentation of this bleeding pattern.

1 March 2006 in The Cerebellum
Verified
Journal Article
Closed access
PDF file
MBMarc A. Brockmann
Marc A. Brockmann
CGChristoph Groden
Christoph Groden
Remote cerebellar hemorrhage remains a complication rarely occurring after supratentorial surgery (< 5%) and presumably even less frequent after spinal surgery. Although the pathomechanisms leading to RCH with its typical bleeding pattern are still not definitely understood, intraor even more likely postoperative loss of larger volumes of CSF seem to be related to this complication. Prognosis significantly depends on severity of hemorrhage and patient age. Outcome in more than 50% of all cases is good with only mild remaining neurological symptoms or complete recovery, while death occurs in ~ 10–15%. Close monitoring of patients undergoing surgery that involves the risk of draining large volumes of CSF is mandatory and patients with postoperative drainage of larger amounts of fluid acquire increased attentiveness. Early detection and correct interpretation of the typical bleeding pattern might help to avoid further aggravation of symptoms. This review will address incidence, typical appearance and pathophysiological considerations, as well as risk factors, treatment options, and outcome related with RCH.

1 April 2003
Verified
Journal Article
Closed access
KLKatrin Lamszus
Katrin Lamszus
UUUlrike Ulbricht
Ulrike Ulbricht
JMJakob Matschke
Jakob Matschke
MBMarc A. Brockmann
Marc A. Brockmann
RFRegina Fillbrandt
Regina Fillbrandt
MWManfred Westphal
Manfred Westphal

1 July 2007 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MBMarc A. Brockmann
Marc A. Brockmann
AGAlf Giese
Alf Giese
KMKathrin Mueller
Kathrin Mueller
FKFinjap Janvier Kaba
Finjap Janvier Kaba
FLFrank Lohr
Frank Lohr
CGChristoph Groden
Christoph Groden
Thrombocytosis, which is defined as a platelet count greater than 400 platelets/nl, has been found to be an independent predictor of shorter survival